New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 9, 2010
07:07 EDTABT, BAC, JNJ, BSXBoston Scientific hires Bank of America to sell two units, Bloomberg reports
Boston Scientific (BSX) has reportedly hired Bank of America (BAC) to advise it on the sale of its Target Therapeutics and neuromodulation units, Bloomberg reports, citing a person with knowledge of the matter. Potential buyers have been approached in recent weeks, the source says. Wells Fargo analyst Larry Biegelsen says the two units could bring in about $2B in a sale. Bernstein analyst Derrick Sung says Johnson & Johnson (JNJ) could buy the neuromodulation unit and Abbott (ABT) may have interest in the Target unit. Reference Link
News For BSX;BAC;ABT;JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
May 20, 2015
08:30 EDTJNJAchillion price target lowered to $16 from $25 at Leerink
Leerink says Achillion's deal with Johnson & Johnson (JNJ) increases the probability that it will be a competitive commercial-stage player in hepatitis C. The firm believes the collaboration limits share downside as well as upside by making the "home-run scenario of great combo data leading to an acquisition less likely." It lowered its price target for Achillion shares to $16 and keeps an Outperform rating on the name.
08:21 EDTBACATM data theft soars to highest rate in two decades, WSJ says
Subscribe for More Information
08:15 EDTJNJJohnson & Johnson CEO Alex Gorsky says won't pursue pure-play strategy
Subscribe for More Information
08:02 EDTJNJJohnson & Johnson to hold a meeting
Subscribe for More Information
07:51 EDTJNJAchillion shares remain undervalued after HCV pact with J&J, says Cowen
Subscribe for More Information
07:33 EDTJNJJ&J to file more than 10 new '$1B potenital' products by 2019
Subscribe for More Information
07:30 EDTJNJAchillion downgraded on valuation at JMP Securities
Subscribe for More Information
06:17 EDTJNJAchillion downgraded to Neutral from Buy at UBS
Subscribe for More Information
05:31 EDTBSXNew study evaluating Boston Scientific Lotus Valve System shows low PVL rates
Subscribe for More Information
May 19, 2015
18:01 EDTBACAflac names Matthew Owenby as Chief Human Resources Officer
Subscribe for More Information
16:10 EDTJNJAchillion enters into collaboration for HCV with Janssen
Achillion (ACHN) announced that it has entered into a worldwide license and collaboration arrangement with Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ), to develop and commercialize one or more of Achillion's lead hepatitis C virus, or HCV, assets which include ACH-3102, ACH-3422, and sovaprevir. Under the terms of the agreement, Achillion will grant Janssen an exclusive, worldwide license to develop and, upon regulatory approval, commercialize HCV products and regimens containing one or more of Achillion's HCV assets. Achillion is eligible to receive a number of payments based upon achievement of specified development, regulatory and sales milestones. Achillion is also eligible to receive tiered royalty percentages between mid-teens and low-twenties based upon future worldwide sales. Janssen will be responsible for all of the development costs within the collaboration and all subsequent costs related to commercialization of the HCV assets. A key objective of the collaboration will be to develop a short-duration, highly effective, pan-genotypic, oral regimen for the treatment of HCV. An initial regimen that will be explored will feature Achillion's ACH-3102, a second-generation NS5A inhibitor currently in Phase 2 clinical studies that has been granted Fast Track designation by the U.S. Food and Drug Administration, in combination with an NS3/4A HCV protease inhibitor plus an NS5B HCV polymerase inhibitor from the collaboration. Additionally, in an equity transaction separate to the exclusive license and collaboration arrangement, Johnson & Johnson Innovation JJDC, Inc. will invest $225M in Achillion and, in return, receive approximately 18.4M newly issued, unregistered shares of Achillion at a price of $12.25 per share. The transactions, including the equity sale, are subject to customary closing conditions, including termination or expiration of any applicable waiting periods under the Hart-Scott-Rodino Act. Transitional clinical development and technology transfer activities under the collaboration are expected to take place over the next several months.
16:01 EDTBACOptions Update; May 19, 2015
iPath S&P 500 VIX Short-Term Futures down 27c to 19.17. Option volume leaders: AAPL BAC WMT MSFT FB TWTR MNKD NFLX T PBR
09:37 EDTBACActive equity options trading on open
Subscribe for More Information
08:02 EDTABTAbbott announces CE Mark for new advancement of Absorb stent system
Subscribe for More Information
07:54 EDTBSXBoston Scientific reports positive data from EVOLVE trial
Subscribe for More Information
06:24 EDTBACU.S. Bancorp and Bank of America win dismissal of mortgage claims, Reuters says
Subscribe for More Information
May 18, 2015
16:00 EDTBACOptions Update; May 18, 2015
Subscribe for More Information
11:23 EDTABTFitch downgrades Abbott's L-T IDR to A; outlook revised to stable
Subscribe for More Information
09:46 EDTBACMPLX enters common unit sales agreement for up to $500M
Subscribe for More Information
09:36 EDTBACActive equity options trading on open
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use